H.R. 3521 · 119th Congress

Clinical Trial Modernization Act

Introduced on May 20, 2025 by Raul Ruiz (D-CA-25). 30 cosponsors, 11 of them from another party. Latest action (May 20, 2025): Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.

Stage
Introduced
Introduced
May 20, 2025
Cosponsors
30
11 from the other party
Policy area
Health
Open in the Congress explorerCongress.govAlert me

Progress

The furthest stage the measure reached. Simple and concurrent resolutions do not go to the President.

  1. Introduced
  2. 2Reported by committee
  3. 3Passed one chamber
  4. 4Passed both chambers
  5. 5Sent to the President
  6. 6Became law

Official title

To modernize clinical trials and remove barriers for participation in clinical trials, and for other purposes.

Summary

By the Congressional Research Service (Introduced in House, May 20, 2025). Public domain.

Clinical Trial Modernization Act

This bill authorizes a grant program and provides certain exemptions to support the participation of individuals in clinical trials.

Specifically, the bill authorizes a grant program to support outreach, education, and recruitment efforts for clinical trials that may benefit certain underrepresented populations or communities in need, such as rural or tribal areas.

The bill also exempts from anti-kickback laws for federal health care programs (1) remuneration that is offered to cover participants' expenses to participate in clinical trials, (2) the provision of free digital health technologies to support participation of underrepresented populations in clinical trials, and (3) payment for participants' cost-sharing obligations in relation to clinical trials.

Finally, the bill exempts up to $2,000 in remuneration that is received for participating in a clinical trial from income tax.

Sponsor and cosponsors

Cosponsors by party as of the day they signed on. Original cosponsors signed on the day of introduction.

Raul RuizD-CA-25Sponsor

Democrats · 19

Republicans · 11

Roll calls

Recorded votes on the measure. Most measures move by voice vote or unanimous consent, which record no individual positions.

No recorded roll call on this measure: it moved by voice vote or unanimous consent, or has not reached the floor.

History

Every action as published, oldest first. Roll calls link to how each member voted.

  1. May 20, 2025Introduced in House
  2. May 20, 2025Introduced in House
  3. May 20, 2025 · HouseReferred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
  4. May 20, 2025 · HouseReferred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.

Committees

Committees and subcommittees the measure was referred to.

Agencies in its committees' jurisdiction

Analisa's mapping of committee jurisdiction to federal agencies; the bill may touch others, or none of these.

Who lobbied on it

Organizations whose lobbying reports (LD-2) name this measure. Spending is what they reported for those quarters on all issues, not on this measure alone.

  1. AMERICAN LUNG ASSOCIATION5 reports
    $990K reported (all issues)
  2. ASSOCIATION FOR CLINICAL ONCOLOGY5 reports
    $1.6M reported (all issues)
  3. American Cancer Society Cancer Action Network, Inc.5 reports
    $10.7M reported (all issues)
  4. McKesson Corporation & affiliates U.S. Oncology and Rx Savings Solutions5 reports
    $3.6M reported (all issues)
  5. McKesson Corporation & affiliates U.S. Oncology and Rx Savings Solutions (Former5 reports
    $150K reported (all issues)
  6. National Health Council5 reports
    $113.9K reported (all issues)
  7. Blood Cancer United (FKA The Leukemia & Lymphoma Society)4 reports
    $1.5M reported (all issues)
  8. Patient Access Network Foundation3 reports
    $120K reported (all issues)
  9. The Susan G. Komen Breast Cancer Foundation, Inc. dba Susan G. Komen3 reports
    $440K reported (all issues)
  10. ASSOCIATION OF CANCER CARE CENTERS (FKA ASSOCIATION OF COMMUNITY CANCER CENTERS)2 reports
    $20K reported (all issues)
  11. BIOTECHNOLOGY INNOVATION ORGANIZATION2 reports
    $3.7M reported (all issues)
  12. BRISTOL-MYERS SQUIBB COMPANY2 reports
    $8M reported (all issues)Federal contractor: BRISTOL-MYERS SQUIBB COMPANY$8.8M in contracts, FY2026AI match · 100%
  13. JOHNSON & JOHNSON SERVICES, INC.2 reports
    $5M reported (all issues)
  14. THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK2 reports
    $520K reported (all issues)Federal contractor: THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORKAI match · 100%
  15. American Cancer Society Action Network, Inc.1 report
    $50K reported (all issues)
  16. AstraZeneca Pharmaceuticals LP1 report
    $1.7M reported (all issues)Federal contractor: ASTRAZENECA PHARMACEUTICALS LP$500 in contracts, FY2026AI match · 100%
  17. Curing Stomach Cancer: Debbie's Dream Foundation1 report
    $15K reported (all issues)
  18. Deadliest Cancers Coalition1 report
  19. Esophageal Cancer Action Network (ECAN)1 report
    $20K reported (all issues)
  20. GSK (fka GLAXOSMITHKLINE INC.)1 report
    $890K reported (all issues)
  21. Hematology Oncology Pharmacy Association1 report
    $50K reported (all issues)
  22. NATIONAL MARROW DONOR PROGRAM1 report
    $290K reported (all issues)Federal contractor: NATIONAL MARROW DONOR PROGRAM$27.8M in contracts, FY2026AI match · 100%
  23. PHARMACEUTICAL RESEARCH & MANUFACTURERS OF AMERICA1 report
    $7.4M reported (all issues)

Reports filed in 2025, 2026.

Sources and method

Every figure on this page traces to these records.

  • Bill status: bills and resolutions, sponsors, actions, subjects and CRS summaries (U.S. Government Publishing Office (GovInfo), from Congress.gov (Library of Congress))GovInfo Bill Status bulk data (Congress.gov; summaries by the Congressional Research Service) · data current to Oct 10, 2026 · loaded Oct 10, 2026 · license: Public domain (U.S. Government work, 17 U.S.C. § 105)
  • Members of Congress, their terms, committees and identifiers (The @unitedstates project (from the Biographical Directory of the U.S. Congress, the House and the Senate))unitedstates/congress-legislators: legislators, committees and current committee membership · data current to Oct 3, 2026 · loaded Oct 3, 2026 · license: CC0 1.0 (public domain dedication)
  • House roll-call votes (Office of the Clerk, U.S. House of Representatives)Office of the Clerk, U.S. House of Representatives, roll-call vote records · data current to Oct 3, 2026 · loaded Oct 3, 2026 · license: Public domain (U.S. Government work, 17 U.S.C. § 105)
  • Senate roll-call votes and DW-NOMINATE scores (Voteview (UCLA Department of Political Science))Lewis, Jeffrey B., Keith Poole, Howard Rosenthal, Adam Boche, Aaron Rudkin, and Luke Sonnet (2026). Voteview: Congressional Roll-Call Votes Database. https://voteview.com/ · data current to Oct 3, 2026 · loaded Oct 3, 2026 · license: Free to use with the required citation
  • Lobbying disclosures (LD-1 registrations, LD-2 quarterly reports, LD-203 contribution reports) (Clerk of the U.S. House of Representatives)Clerk of the House, Lobbying Disclosure Act filings (organizations only; lobbyists' names are not loaded) · data current to Oct 10, 2026 · loaded Oct 10, 2026 · license: Public domain (U.S. Government work, 17 U.S.C. § 105)
  • Positions are shown only where a roll call recorded them; voice votes and unanimous consent record none.
  • Money and votes are shown side by side; neither explains the other.